0.652
-0.02 (-2.53%)
| Penutupan Terdahulu | 0.669 |
| Buka | 0.660 |
| Jumlah Dagangan | 239,426 |
| Purata Dagangan (3B) | 6,644,868 |
| Modal Pasaran | 29,061,482 |
| Harga / Jualan (P/S) | 2.42 |
| Harga / Buku (P/B) | 15.18 |
| Julat 52 Minggu |
| Margin Keuntungan | -63.52% |
| Margin Operasi (TTM) | -7.46% |
| EPS Cair (TTM) | -1.31 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -11.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 300.69% |
| Nisbah Semasa (MRQ) | 0.810 |
| Aliran Tunai Operasi (OCF TTM) | 3.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 5.51 M |
| Pulangan Atas Aset (ROA TTM) | -2.38% |
| Pulangan Atas Ekuiti (ROE TTM) | -138.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Bercampur | Bercampur |
| Medical Instruments & Supplies (Global) | Bercampur | Menurun | |
| Stok | Harvard Bioscience, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.33 |
|
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.27% |
| % Dimiliki oleh Institusi | 69.66% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Jan 2026 | Pengumuman | Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth |
| 17 Dec 2025 | Pengumuman | Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |